Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease

Overactivation of Src has been linked to the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). This phase 2, multisite study assessed the efficacy and safety of bosutinib, an oral dual Src/Bcr-Abl tyrosine kinase inhibitor, in patients with ADPKD. Patients with ADPKD, eGFR≥60 ml/...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Am Soc Nephrol
Huvudupphovsmän: Tesar, Vladimir, Ciechanowski, Kazimierz, Pei, York, Barash, Irina, Shannon, Megan, Li, Ray, Williams, Jason H., Levisetti, Matteo, Arkin, Steven, Serra, Andreas
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Nephrology 2017
Ämnen:
Clinical Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5661280/
https://ncbi.nlm.nih.gov/pubmed/28838955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016111232
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk